| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
,
Departments of
*
Pathology,
Medicine, and
Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Clinical trials evaluating a newly engineered version of the mAb OKT3, termed hOKT3
1(Ala-Ala), have shown that it is possible to engage the TCR/CD3 complex in the absence of costimulation to transduce a signal that triggers an effector function distinct from apoptosis on a subset of T cells (5). Based on earlier work in mice, it appears that the effects of hOKT31(Ala-Ala) are largely the result of mutations in the Fc portion, which dramatically reduce its ability to be bound by host FcRs, hence preventing extensive cross-linking of the TCR/CD3 complexes engaged by the Ab (3). Furthermore, it was reported in both mice and humans that these non-cross-linking anti-CD3 Abs act only on activated, not naive T cells (3, 5), and that engagement of the TCR/CD3 complex with minimal cross-linking delivers an activation signal to previously activated human T cells resulting in immune modulation, possibly through IL-10 production (4).
In this report, we characterize biochemical signaling pathways that may contribute to the distinct effector function of T cells stimulated by varying degrees of TCR cross-linking. Using an in vitro stimulation protocol that allows discrete control over the relative strength of TCR/CD3 complex cross-linking, we provide evidence for differential kinetics and duration of activation for the mitogen-activated protein kinase pathway, a mechanism for how it is regulated, and how this may impact T cell effector function.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
PBMC were prepared on a Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO) density gradient, and fresh T cells were purified by negative magnetic selection with Abs to CD14, CD16, CD19, CD36, CD56, and glycophorin A (StemCell Technologies, Vancouver, British Columbia, Canada). This resulted in >95% CD3+ cell population as determined by flow-cytometric analysis. Effector peripheral blood T lymphoblasts (PBT)3 were prepared as previously described (6). After 10–14 days in culture with IL-2, >99% of the cells are CD3+, CD4+, and CD45RO+ T cells, as determined by flow cytometry (7), compared with freshly isolated PBT that are 54% naive T cells (CD45RA+) and 60% CD4+ (8). The mean channel fluorescence for CD3 was indistinguishable between freshly isolated PBT and effector PBT lymphoblasts (9). The following reagents were used: anti-phosphotyrosine (PY20-HRP; BD Transduction Labs, Lexington, KY), rabbit anti-phospho 
-associated protein of 70 kDa (ZAP-70) (Y319), rabbit anti-phospho extracellular signal-regulated kinase (ERK)-1/2, rabbit anti-phospho Akt (S473), rabbit anti-ERK-1/2, rabbit anti-Akt, and LY294002 (Cell Signaling Technology, Beverly, MA), rabbit anti-Fos (Upstate Biotechnology, Lake Placid, NY), rabbit anti-GAPDH (Trevigen, Gaithersburg, MD), HRP-conjugated secondary Abs (Santa Cruz Biotechnology, Santa Cruz, CA), and GelCode Blue Stain Reagent (Pierce, Rockford, IL).
T cell stimulation
PBT, rested overnight (unless otherwise indicated) in the absence of IL-2 (RPMI 1640, 10% FCS, 25 mM HEPES) at 37°C, were resuspended (5 x 106 cells/100 µl) in RPMI 1640 and 25 mM HEPES, and incubated at 37°C for 5 min. Cells were stimulated via TCR/CD3 complex engagement with soluble OKT3 Ab (Ortho Diagnostic Systems, Raritan, NJ) alone, or OKT3 cross-linked by sheep anti-mouse F(ab')2 (Sigma-Aldrich) at 37°C for the indicated times, immediately followed by the addition of 100 µl of 2x Laemmli sample buffer and boiled for 5 min. Unstimulated cells received only the sheep anti-mouse F(ab')2.
Western blotting
Proteins were separated by SDS-PAGE on a 10% gel under reducing conditions and transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA) (6). Membranes were blocked and incubated with Abs as previously described (6). Detection of HRP-conjugated Abs was performed using SuperSignal (Pierce) and chemiluminescence recorded on Hyperfilm ECL (Amersham, Arlington Heights, IL).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In light of recent advances delineating differences among naive, memory, and effector T cells with regard to expression and use of signaling molecules (10, 11), we examined potential signaling differences in freshly isolated vs effector T cells (Fig. 1). As shown in the top panels of Fig. 1, the ability to induce global protein tyrosine phosphorylation via OKT3 cross-linking of the TCR/CD3 complex at 2 and 5 min is nearly identical in freshly isolated and effector PBT. In agreement with total phosphotyrosine, the phosphorylation of ZAP-70 at Y319 is also similar between freshly isolated and effector PBT (Fig. 1, middle panels). Although these activation events proximal to the TCR are indistinguishable, there is a marked difference in the ability to initiate the ERK second messenger pathway (Fig. 1, lower panels). Freshly isolated PBT, consisting of naive and memory T cells, are completely refractory to p44 ERK-1 phosphorylation after TCR/CD3 cross-linking at 2 and 5 min, and display only a slight increase in p42 ERK-2 phosphorylation (Fig. 1, lower panel). However, the ERK signaling pathway does remain intact in these cells, because inhibition of tyrosine phosphatases (data not shown) in freshly isolated PBT induces a strong phospho-ERK response, and pharmacological activation of protein kinase C stimulates ERK phosphorylation in primary lymphocytes (12). Stimulation of freshly isolated PBT for 20 min does not alter the activation of either ERK isoform (data not shown). In contrast, ERK-1/2 phosphorylation is prominently induced in effector PBT upon TCR/CD3 cross-linking (Fig. 1, lower panel). Total expression of ERK protein is indistinguishable between freshly isolated and effector PBT from matched donors (Fig. 1).
|
The kinetics and duration of ERK phosphorylation vary with the degree of TCR/CD3 complex cross-linking
To address our hypothesis that differential TCR engagement may affect the ERK pathway, effector PBT were stimulated with 0.1–10 µg/ml soluble OKT3, either alone or cross-linked with 10 µg/ml sheep anti-mouse F(ab')2 (Fig. 2). When the cross-linking reagent is present, all doses of OKT3 lead to a strong induction of ERK at 1 min. In addition, the duration of ERK phosphorylation was inversely related to the relative degree of TCR cross-linking. As the ratio of cross-linker to OKT3 decreases from 100:1 to 1:1, ERK remains phosphorylated for a greater length of time (Fig. 2, left panels). In contrast, when effector PBT are stimulated with soluble OKT3 only at doses from 0.1 to 10 µg/ml, there is a much more gradual yet sustained ERK phosphorylation (Fig. 2, right panels). The levels of total ERK protein are unchanged after stimulation (data not shown). Additionally, the kinetics and duration of this second messenger activation are strikingly similar throughout the 100-fold difference in OKT3 concentration.
|
To gain an understanding of the mechanism by which ERK activity is induced under the weakly stimulatory condition (non-cross-linked OKT3), we considered the potential for cross-talk between this second messenger pathway and the PI-3K pathway (Fig. 3). It has previously been shown in mouse lymph node cells that anti-CD3 stimulation with concurrent inhibition of PI-3K activity leads to diminished activity of ERK-2 (13). Furthermore, in nonimmune cells, ERK activity is sensitive to PI-3K inhibition when relatively few growth factor receptors are engaged, but more resistant when a larger number of receptors are activated (14). Because IL-2 signaling transduces the PI-3K pathway (15, 16), we compared the ability to induce ERK activation in effector PBT taken directly from culture with IL-2 vs those removed from IL-2 for 16 h before stimulation through the TCR. When PBT are deprived of IL-2, there is little detectable basal PI-3K activity, as evidenced by the lack of phosphorylation on Akt/PKB at S473 (Fig. 3A, upper panel, lane 1). Upon stimulation with 10 µg/ml soluble OKT3, phospho-Akt is increased (Fig. 3A, upper panel, lanes 2–4). As the levels of phospho-Akt increase over time, so does the level of phospho-ERK (Fig. 3A, lower panel). Levels of ERK and Akt protein are unchanged after stimulation and unaffected by the absence or presence of IL-2 for the final 16 h of incubation (Fig. 3). In contrast, when PBT are continuously cultured with IL-2, basal PI-3K activity is elevated, yet the level of phospho-Akt does not change appreciably when 10 µg/ml soluble OKT3 is added (Fig. 3B, upper panel). As proposed, elevated PI-3K activity before stimulation coincides with a more rapid induction of ERK phosphorylation within 1 min of 10 µg/ml soluble OKT3 addition (Fig. 3B, lane 2), suggesting that, in effector PBT, the level of PI-3K activity may set thresholds for ERK activation.
|
The finding that the relative activity of PI-3K in PBT affects the kinetics of ERK activation under weakly stimulatory conditions prompted us to examine whether ERK phosphorylation is induced when PI-3K activity is inhibited by the pharmacological agent LY294002 (Fig. 4). Effector PBT were stimulated with 10 µg/ml soluble OKT3 alone (Fig. 4A) or cross-linked by a secondary Ab (B) in the presence or absence of 50 µM LY294002. After OKT3 stimulation alone, there is a low level of constitutive PI-3K activity (Fig. 4A, upper panel, lane 1) that correlates with intermediate kinetics of ERK phosphorylation (lower panel, lane 2). The duration of ERK phosphorylation under this stimulatory regimen is similar to that shown in Fig. 2, with a high degree of ERK-1/2 phosphorylation at 60 min (Fig. 4A, lower panel, lane 5) that persists for at least 3 h (data not shown). When PI-3K is inhibited by pretreatment of PBT with 50 µM LY294002 for 15 min at 37°C, phospho-Akt induction is completely blocked for at least the first 60 min after addition of 10 µg/ml soluble OKT3 (Fig. 4A, upper panel, lanes 6–10). This is paralleled by a striking inhibition of ERK phosphorylation, most prominently on p44 ERK-1 (Fig. 4A, lower panel, lanes 6–10), over the same time course.
|
The kinetics and duration of ERK activity modulate the induction and stability of the immediate early gene product c-Fos: implications for differential effector function
ERK induces different effector functions depending on whether its activity is transient or sustained (17). However, only recently has a molecular mechanism been proposed to account for the ability of the cell to respond to the duration of ERK activation (18). Certain proteins, including several immediate early gene products, possess an amino acid sequence referred to as a DEF domain that acts as a docking site for activated ERK. Recruitment of active ERK promotes Ser/Thr phosphorylation that alters the target protein’s stability, such as c-Fos, or may lead to ERK-1/2-mediated trans-phosphorylation of other proteins, including transcription factors (18). We predicted that varying the kinetics and duration of ERK activation in effector T cells would regulate the expression and stability of c-Fos, a DEF domain-containing protein that is part of the AP-1 transcriptional complex (Fig. 5). c-Fos induction is slightly more rapid when soluble OKT3 is cross-linked by a secondary Ab vs OKT3 alone (Fig. 5, lane 2 vs lane 5). However, under weakly stimulatory conditions (non-cross-linked OKT3), c-Fos protein levels remain higher for a longer time compared with when OKT3 is cross-linked (Fig. 5, lane 4 vs lane 7). These results mirror the duration of ERK activation and suggest that other DEF domain-containing proteins in PBT may be similarly affected by the kinetics and duration of ERK activation, leading to potentially divergent effector functions.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The apparent linearity of the biochemical reactions mediating the Ras-Raf-mitogen-activated protein kinase kinase-ERK pathway disguises a deceptively complex signaling network capable of regulating such diverse functions as proliferation, cytokine and growth factor production, differentiation, and cell cycle regulation. New models to explain how such a ubiquitous signaling module as the ERK pathway can attain specificity under differing stimulatory conditions in the same cell have just recently emerged. The activity of the ERK pathway exhibits complex behavior, existing in monostable or bistable states depending on the status of negative feedback loops. Furthermore, it appears that the stimulus strength, which modulates the kinetics of ERK activation, regulates the induction of these negative-feedback loops (19). Application of these new concepts to the results presented in this report may explain the rapid decline in ERK phosphorylation under stimulatory conditions of high signal strength (Fig. 2, left panels). It is plausible that, in the context of the more potent stimulatory regimen, there is a more rapid induction of negative-feedback loops. Conversely, lower signal strength could delay initiation of negative mediators. In agreement with the latter statement, there is a remarkably similar pattern of sustained ERK phosphorylation when the TCR/CD3 complex is engaged with no cross-linking over a 100-fold concentration range of OKT3 (Fig. 2, right panels). As our understanding of differential signaling through the TCR/CD3 complex via extent of OKT3 cross-linking evolves, it will be important to compare these results with those of the more mature field of altered peptide ligands and TCR signaling (20).
The functional consequences of modulating ERK phosphorylation may be explained in part by a recent report postulating a mechanism for the molecular interpretation of ERK signal duration (18). Proteins possessing an ERK targeting motif, termed a DEF domain, can serve as sensors for transient vs sustained ERK activation and regulate downstream pathways accordingly, such as gene transcription. As we demonstrate in this study, sustained ERK activation correlates with continued c-Fos (which possesses a DEF domain) protein expression (Fig. 5). Our results demonstrate that the duration of ERK activation in PBT, determined in large part by the strength of the TCR signal, can have important functional consequences, regulating the expression of transcription factors.
An additional feature that contributes to TCR-mediated ERK phosphorylation, based on results reported here, is the activation status of the T cell population. We show that the PI-3K pathway lowers the threshold for ERK phosphorylation when the TCR/CD3 complex is stimulated with a lower avidity ligand (Fig. 3). Targeted pharmacological inhibition of PI-3K provides evidence that this pathway is essential for the induction of ERK activity under weakly stimulatory conditions (Fig. 4), as encountered clinically with hOKT31(Ala-Ala). Interestingly, it was previously reported that only recently activated T cells respond to hOKT31(Ala-Ala) (5), which in the studies reported here are the subset of PBT capable of significant induction of PI-3K activity. These clinical findings add further support to our hypothesis that limited engagement of the TCR/CD3 complex preferentially induces sustained ERK activation in a PI-3K-dependent manner in the subset of recently activated or effector PBT. Furthermore, sustained phosphorylation of ERK will likely target proteins with DEF domains, leading to their prolonged expression or activation. The most interesting prospect in this regard is the DEF domain-containing Th2-predominant transcription factor GATA-3, which is expressed in these effector PBT (data not shown). We propose that sustained ERK activation may be associated with increased transcriptional activity of GATA-3, hence biasing the immune response toward a Th2 cell phenotype.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Alan D. Levine, Department of Medicine, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106-4952. E-mail address: alan.levine{at}case.edu
3 Abbreviations used in this paper: PBT, peripheral blood T lymphoblast; ZAP-70, -associated protein of 70 kDa; ERK, extracellular signal-regulated kinase; PI-3K, phosphatidylinositol-3 kinase; DEF, docking site for ERK (FXFP).
Received for publication December 10, 2003. Accepted for publication March 19, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1(Ala-Ala). J. Clin. Invest. 111:409.[Medline]
subunit and Syk kinase replace the CD3 -chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J. Immunol. 170:4189.This article has been cited by other articles:
|
|
 |
|
  A. E. Schade, G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Blood, February 1, 2008; 111(3): 1366 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-P. Liu, Y.-C. Kuo, C.-C. Shen, M.-H. Wu, J.-F. Liao, Y.-L. Lin, C.-F. Chen, and W.-J. Tsai (S)-Armepavine inhibits human peripheral blood mononuclear cell activation by regulating Itk and PLC{gamma} activation in a PI-3K-dependent manner J. Leukoc. Biol., May 1, 2007; 81(5): 1276 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Kemp, L. Wille, C. L. Lewis, L. B. Nicholson, and D. A. Lauffenburger Quantitative Network Signal Combinations Downstream of TCR Activation Can Predict IL-2 Production Response J. Immunol., April 15, 2007; 178(8): 4984 - 4992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ibanez, M.-R. Sarrias, M. Farnos, I. Gimferrer, C. Serra-Pages, J. Vives, and F. Lozano Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor J. Immunol., July 15, 2006; 177(2): 1152 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis Blood, June 15, 2006; 107(12): 4834 - 4840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Kogkopoulou, E. Tzakos, G. Mavrothalassitis, C. T. Baldari, F. Paliogianni, H. A. Young, and G. Thyphronitis Conditional up-regulation of IL-2 production by p38 MAPK inactivation is mediated by increased Erk1/2 activity J. Leukoc. Biol., May 1, 2006; 79(5): 1052 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rubenfeld, J. Guo, N. Sookrung, R. Chen, W. Chaicumpa, V. Casolaro, Y. Zhao, V. Natarajan, and S. Georas Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L66 - L74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Robertson, L. R. Mireau, and H. L. Ostergaard A Role for Phosphatidylinositol 3-Kinase in TCR-Stimulated ERK Activation Leading to Paxillin Phosphorylation and CTL Degranulation J. Immunol., December 15, 2005; 175(12): 8138 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nekrasova, C. Shive, Y. Gao, K. Kawamura, R. Guardia, G. Landreth, and T. G. Forsthuber ERK1-Deficient Mice Show Normal T Cell Effector Function and Are Highly Susceptible to Experimental Autoimmune Encephalomyelitis J. Immunol., August 15, 2005; 175(4): 2374 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Clemmons and L. A. Maile Interaction between Insulin-Like Growth Factor-I Receptor and {alpha}V{beta}3 Integrin Linked Signaling Pathways: Cellular Responses to Changes in Multiple Signaling Inputs Mol. Endocrinol., January 1, 2005; 19(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
cross-linking (OKT3; 10 µg/ml). Samples were analyzed by SDS-PAGE and immunoblotting for phosphotyrosine, phospho-Y319-ZAP-70, and phospho-ERK-1/2. Immunoblotting for total ERK expression, run in parallel, is shown for donor-matched freshly isolated and effector PBT. Protein loading between lanes was additionally controlled by GAPDH immunoblotting (data not shown).
